期刊
CANADIAN JOURNAL OF DIABETES
卷 37, 期 5, 页码 319-326出版社
ELSEVIER
DOI: 10.1016/j.jcjd.2013.07.062
关键词
cardiovascular diseases; cholesterol efflux; diabetes; dyslipidemia; ER stress; HDL; insulin resistance; triglycerides
资金
- Canadian Institutes for Health Research (CIHR) [MOP275369]
- CIHR China-Canada Joint Health Research Initiative grant
- Heart and Stroke Foundation of Ontario [NA 6331]
Diabetic dyslipidemia is characterized by hepatic very low density lipoprotein (VLDL) and intestinal chylomicron overproduction, reduced high density lipoprotein cholesterol (HDL-C) level, increased propensity of small dense LDL (sdLDL) and increased postprandial lipemia. This dyslipidemic profile is also strongly linked to other features of the metabolic syndrome. Diabetic dyslipidemia is a well-recognized risk factor for atherosclerotic cardiovascular diseases. Currently, statins remain the first line therapy primarily through reducing the atherogenic LDL. Clinical trials on other lipid modifying agents were met with variable success in selective patient populations. Emerging new insights into the pathophysiology of lipid metabolism, in general, and diabetic dyslipidemia, in particular, have opened up potentially novel therapeutic strategies to further reduce the risk associated with diabetic dyslipidemia and insulin resistant state. (C) 2013 Canadian Diabetes Association
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据